Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc. Fundamental Analysis
Intellipharmaceutics International Inc. (IPCI.TO) shows moderate financial fundamentals with a PE ratio of -0.66, profit margin of -44.01%, and ROE of 30.88%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -4072.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze IPCI.TO's fundamental strength across five key dimensions:
Efficiency Score
WeakIPCI.TO struggles to generate sufficient returns from assets.
Valuation Score
ExcellentIPCI.TO trades at attractive valuation levels.
Growth Score
WeakIPCI.TO faces weak or negative growth trends.
Financial Health Score
ModerateIPCI.TO shows balanced financial health with some risks.
Profitability Score
WeakIPCI.TO struggles to sustain strong margins.
Key Financial Metrics
Is IPCI.TO Expensive or Cheap?
P/E Ratio
IPCI.TO trades at -0.66 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, IPCI.TO's PEG of -0.01 indicates potential undervaluation.
Price to Book
The market values Intellipharmaceutics International Inc. at -0.18 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 0.14 times EBITDA. This is generally considered low.
How Well Does IPCI.TO Make Money?
Net Profit Margin
For every $100 in sales, Intellipharmaceutics International Inc. keeps $-44.01 as profit after all expenses.
Operating Margin
Core operations generate -43.37 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $30.88 in profit for every $100 of shareholder equity.
ROA
Intellipharmaceutics International Inc. generates $-2.02 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Intellipharmaceutics International Inc. generates limited operating cash flow of $-1.39M, signaling weaker underlying cash strength.
Free Cash Flow
Intellipharmaceutics International Inc. generates weak or negative free cash flow of $-1.39M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.04 in free cash annually.
FCF Yield
IPCI.TO converts -73.03% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-0.66
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.01
vs 25 benchmark
P/B Ratio
Price to book value ratio
-0.18
vs 25 benchmark
P/S Ratio
Price to sales ratio
28.90
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
-0.22
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.04
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.31
vs 25 benchmark
ROA
Return on assets percentage
-2.02
vs 25 benchmark
ROCE
Return on capital employed
0.27
vs 25 benchmark
How IPCI.TO Stacks Against Its Sector Peers
| Metric | IPCI.TO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -0.66 | 27.91 | Better (Cheaper) |
| ROE | 30.88% | 687.00% | Weak |
| Net Margin | -4400.55% | -45285.00% (disorted) | Weak |
| Debt/Equity | -0.22 | 0.33 | Strong (Low Leverage) |
| Current Ratio | 0.04 | 2795.76 | Weak Liquidity |
| ROA | -201.98% | -13557.00% (disorted) | Weak |
IPCI.TO outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Intellipharmaceutics International Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation